MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1
dc.creator | Flower, Michael | |
dc.creator | Lomeikaite, Vilija | |
dc.creator | Ciosi, Marc | |
dc.creator | Cumming, Sarah | |
dc.creator | Morales Montero, Fernando | |
dc.creator | Lo, Kitty | |
dc.creator | Hensman Moss, Davina | |
dc.creator | Jones, Lesley | |
dc.creator | Holmans, Peter A. | |
dc.creator | TRACK-HD Investigators | |
dc.creator | OPTIMISTIC Consortium | |
dc.creator | Monckton, Darren G. | |
dc.creator | Tabrizi, Sarah J. | |
dc.date.accessioned | 2020-01-17T20:06:56Z | |
dc.date.available | 2020-01-17T20:06:56Z | |
dc.date.issued | 2019-07 | |
dc.description.abstract | Huntington’s disease and myotonic dystrophy type 1. A recent Huntington’s disease genome-wide association study found rs557874766, an imputed single nucleotide polymorphism located within a polymorphic 9 bp tandem repeat in MSH3/DHFR, as the variant most significantly associated with progression in Huntington’s disease. Using Illumina sequencing in Huntington’s disease and myotonic dystrophy type 1 subjects, we show that rs557874766 is an alignment artefact, the minor allele for which corresponds to a three-repeat allele in MSH3 exon 1 that is associated with a reduced rate of somatic CAG CTG expansion (P = 0.004) and delayed disease onset (P = 0.003) in both Huntington’s disease and myotonic dystrophy type 1, and slower progression (P = 3.86 10 7) in Huntington’s disease. RNA-Seq of whole blood in the Huntington’s disease subjects found that repeat variants are associated with MSH3 and DHFR expression. A transcriptome-wide association study in the Huntington’s disease cohort found increased MSH3 and DHFR expression are associated with disease progression. These results suggest that variation in the MSH3 exon 1 repeat region influences somatic expansion and disease phenotype in Huntington’s disease and myotonic dystrophy type 1, and suggests a common DNA repair mechanism operates in both repeat expansion diseases. | es_ES |
dc.description.procedence | UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones en Salud (INISA) | es_ES |
dc.description.sponsorship | UK DementiaResearch Institute/[]//Reino Unido | es_ES |
dc.description.sponsorship | Medical Research Council/[MR/L010305/1]/MRC/Reino Unido | es_ES |
dc.description.sponsorship | European Union’s Seventh Framework Programme/[2012-305121]/FP7 2007-2013/Unión Europea | es_ES |
dc.description.sponsorship | Rosetrees Trust/[JS16/M574]//Reino Unido | es_ES |
dc.identifier.citation | https://academic.oup.com/brain/article/142/7/1876/5520687 | |
dc.identifier.doi | https://doi.org/10.1093/brain/awz115 | |
dc.identifier.issn | 1460-2156 | |
dc.identifier.issn | 0006-8950 | |
dc.identifier.uri | https://hdl.handle.net/10669/80324 | |
dc.language.iso | en_US | es_ES |
dc.rights | acceso abierto | |
dc.source | Brain, vol. 142(7), 1876-1886 | es_ES |
dc.subject | Huntington’s disease | es_ES |
dc.subject | myotonic dystrophy | es_ES |
dc.subject | transcriptomics | es_ES |
dc.subject | movement disorders | es_ES |
dc.subject | association study | es_ES |
dc.title | MSH3 modifies somatic instability and disease severity in Huntington’s and myotonic dystrophy type 1 | es_ES |
dc.type | artículo original |